読み込み中
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
前日終値
$3.07
−$0.25 · -7.53%
時間外
$3.10
+$0.03 · +0.98%
10月8日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
日中レンジ
現在 $3.07
52週レンジ
現在 $3.07
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
61
割安
センチメント
56
まちまち
リスク
52
やや高いリスク
モメンタム
62
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
日中レンジ
現在 $3.07
52週レンジ
現在 $3.07
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（AUD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | — | 543.89万 AUD | 401.93万 AUD | 391.63万 AUD | 512.35万 AUD |
| 売上原価 | 11.3万 AUD | 12.75万 AUD | 21.43万 AUD | 28.51万 AUD | 36.47万 AUD |
| 粗利益 | −11.3万 AUD | 531.14万 AUD | 380.5万 AUD | 363.13万 AUD | 475.89万 AUD |
| 研究開発 | 1724.43万 AUD | 1440.43万 AUD | 1864.4万 AUD | 1319.86万 AUD | 1474.58万 AUD |
| 販売・一般管理 | 1044.2万 AUD | 548.14万 AUD | 476.26万 AUD | 503.94万 AUD | 551.39万 AUD |
| 営業費用 | 2768.63万 AUD | 1988.57万 AUD | 2340.67万 AUD | 1823.8万 AUD | 2025.97万 AUD |
| 受取利息 | 167.91万 AUD | 44.63万 AUD | 26.84万 AUD | 1.64万 AUD | 2504 AUD |
| 減価償却費と償却費 | 11.3万 AUD | 13.97万 AUD | 14.75万 AUD | 10.23万 AUD | 5.42万 AUD |
| 営業利益 | −2779.93万 AUD | −1457.43万 AUD | −1960.17万 AUD | −1463.61万 AUD | −1550.2万 AUD |
| 純利益 | −2288.96万 AUD | −1214.78万 AUD | −1912.35万 AUD | −1380.65万 AUD | −1284.71万 AUD |
会社概要が更新されました 2026年10月9日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
